Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90

Author: Benzinga Newsdesk | April 22, 2024 12:44pm

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $82 to $90.

Posted In: ITCI